Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphatic Metastasis × Nivolumab × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Genitourinary 1

Conditions

Ovarian Neoplasms 34 Carcinoma, Non-Small-Cell Lung 20 Uterine Cervical Neoplasms 19 Melanoma 18 Carcinoma, Renal Cell 15 Endometrial Neoplasms 14 Carcinoma, Transitional Cell 13 Stomach Neoplasms 12 Triple Negative Breast Neoplasms 11 Fallopian Tube Neoplasms 11 Colorectal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 9 Pancreatic Neoplasms 8 Head and Neck Neoplasms 8 Carcinoma, Ovarian Epithelial 8 Carcinoma, Hepatocellular 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Carcinoma, Merkel Cell 7 Neoplasms 6 Cholangiocarcinoma 6 Mesothelioma 5 Esophageal Neoplasms 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Neoplasm Metastasis 4 Carcinosarcoma 4 Vulvar Neoplasms 3 Lymphoma 3 Lung Neoplasms 3

Interventions

sarcolipin 1 TP protocol 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Lymph Node Excision 1 Ipilimumab 1 Drug Therapy 1 Diffusion Magnetic Resonance Imaging 1 Cytoreduction Surgical Procedures 1 Cisplatin 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05504642 2023-04-18

CERAD-IMMUNE

Universitätsklinikum Köln

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡